CJC-1295 and GHRP-6 Blend Reconstitution: Step-by-Step Lab Guide
CJC-1295 and GHRP-6 Blend Reconstitution: Step-by-Step Lab Guide
The CJC-1295 and GHRP-6 blend represents a sophisticated combination of synthetic peptides designed for advanced in vitro research applications. CJC-1295, a growth hormone-releasing hormone analog, works synergistically with GHRP-6, a hexapeptide that stimulates growth hormone secretion through ghrelin receptor activation. This lyophilised formulation maintains peptide stability during storage while requiring careful reconstitution protocols to ensure optimal research outcomes in laboratory settings.
Materials Required
CJC-1295 + GHRP-6 Blend lyophilised vial (2mg/2mg)
Bacteriostatic water for injection (BWFI) or sterile water for injection
Precision analytical balance (±0.1mg accuracy)
Sterile insulin syringes (1mL capacity with 29-31 gauge needles)
Sterile glass vials or microcentrifuge tubes for aliquoting
Laboratory-grade micropipettes with sterile tips
Laminar flow hood or biosafety cabinet
70% isopropanol solution
Sterile gauze pads
Vortex mixer (optional)
Laboratory refrigeration unit (2-8°C)
Pre-Reconstitution Preparation
Establish aseptic conditions within a laminar flow hood or biosafety cabinet before initiating the reconstitution process. Remove the lyophilised vial from refrigerated storage and allow equilibration to room temperature for approximately 15-20 minutes. This temperature adjustment prevents thermal shock that could potentially denature the peptide structures. Examine the lyophilised cake for uniformity and absence of discoloration, which should appear as a white or off-white solid mass.
Prepare the workspace by thoroughly cleaning all surfaces with 70% isopropanol solution. Organize required materials within the sterile field, ensuring easy access while maintaining contamination-free conditions. Calculate the desired final concentration based on experimental requirements, considering both peptides are present in equal 2mg quantities within the vial.
Step-by-Step Reconstitution Protocol
Step 1: Sanitize the rubber stopper of both the peptide vial and solvent container using 70% isopropanol. Allow complete evaporation of the alcohol before proceeding to prevent potential peptide precipitation.
Step 2: Draw the calculated volume of bacteriostatic water or sterile water into a sterile syringe. For optimal concentration control, consider drawing slightly more than the target volume to account for dead space within the syringe assembly.
Step 3: Insert the needle through the rubber stopper at a 45-degree angle, avoiding direct impact with the lyophilised cake. Direct contact with the peptide mass may cause foaming or aggregation, compromising peptide integrity.
Step 4: Slowly inject the solvent along the vial wall, allowing gentle flow over the lyophilised material. Avoid forceful injection that creates turbulence or excessive agitation of the peptide cake.
Step 5: Remove the syringe and gently swirl the vial in circular motions to facilitate dissolution. Avoid vigorous shaking or vortexing, which may lead to peptide denaturation or aggregation. Complete dissolution typically occurs within 2-3 minutes of gentle agitation.
Step 6: Inspect the reconstituted solution for complete clarity and absence of particulates. The final solution should appear colorless and transparent without visible precipitation or cloudiness.
Concentration Options
1.0 mL
2.0 mg/mL
4.0 mg/mL
2.0 mL
1.0 mg/mL
4.0 mL
0.5 mg/mL
Storage Conditions
Store the reconstituted peptide blend immediately at 2-8°C in the original vial or transfer to appropriately labeled sterile containers. For extended storage beyond 30 days, consider dividing the solution into single-use aliquots to minimize freeze-thaw cycles. Long-term storage at -20°C or -80°C may be appropriate for certain experimental timelines, though peptide stability should be verified through analytical testing.
Protect the reconstituted solution from direct light exposure by wrapping vials in aluminum foil or storing in amber-colored containers. Document reconstitution date, concentration, and storage conditions on appropriate laboratory labels for proper inventory management.
Research Application Notes
Element SARMs provides this CJC-1295 and GHRP-6 blend specifically for in vitro research applications investigating growth hormone release mechanisms and peptide receptor interactions. The reconstituted solution maintains stability for cell culture studies, receptor binding assays, and biochemical pathway investigations when stored under appropriate conditions. Researchers should validate peptide concentrations through analytical methods such as HPLC or mass spectrometry to ensure experimental reproducibility and accuracy in their laboratory protocols.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML